Vessell brings to SHINE more than 25 years of experience in healthcare, manufacturing and financial services, including a Six Sigma Master Black Belt certification for his leadership, service and team management. He most recently served as the US Nuclear Medicine Supply Chain Manager for GE Healthcare’s Pharmaceutical Diagnostics (PDx) Group, where he oversaw the production of various radiopharmaceuticals, from raw materials production first by cyclotron to the final drug formulation. Additionally, he was also responsible for leading PDx’s network of 31 radiopharmacies across the United States prior to their divestiture, successfully delivering over 2 million prescription doses of nuclear medicine to partner hospitals and clinics on an annual basis. .
“Chris brings a wealth of healthcare and customer management expertise to the SHINE team,” said Greg Piefer, founder and CEO of SHINE. “As we continue to make significant progress in our production process for Lu-177, his knowledge and proven leadership will help us provide patients with the best cancer treatment globally.”
“I am thrilled to bring my experience to such a talented and visionary team at SHINE,” said Vessell. “Their technology and vision for the future will be a game changer as the company continues to innovate new methods of nuclear medicine and deliver cancer therapies that make immeasurable differences for patients and their families.”
Vessell holds bachelor’s and master’s degrees in industrial engineering from the University of Illinois. Vessel will be based on the growth of SHINE Janesville head office, which today employs more than 250 people.
About SHINE Technologies
SHINE is a next-generation nuclear technology company, deploying cutting-edge fusion technology to create an evolutionary path to fusion energy. Based in the south Wisconsinwhose head office is at Janesvilleand with a future site under development at Europe, SHINE deploys its safe, cost-effective and environmentally friendly technology in a phased approach. SHINE’s systems are used for industrial component imaging in the aerospace, defense, transportation, energy and other industries. And SHINE’s proprietary isotope production processes create unsupported molybdenum-99 and lutetium-177 used in tens of thousands of daily procedures to diagnose and treat heart disease and advanced cancers. For more information, follow SHINE on Facebook, LinkedIn and Twitter.
SOURCE SHINE Technologies, LLC